Beijing Intellectual Property Court Upholds Validity of Novartis’ Entresto Patent
The Beijing Intellectual Property Court (BIPC) has issued a judgment that reaffirms the validity and...
NYSE: NVS
Sandoz Plans USD 90 Million Biosimilar Development Center in Slovenia by 2026
The Sandoz unit of Switzerland-based Novartis (NYSE: NVS) has announced plans to construct a biosimilar...
Novartis Q2 2023 Results Exceed Expectations with 9% YOY Sales Growth
Swiss pharmaceutical major Novartis AG (NYSE: NVS) has reported its financial results for the second...
Novartis Acquires DTx Pharma and Its FALCON Technology for Up to $1 Billion
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced the acquisition of DTx Pharma Inc., a...
Novartis Terminates TIGIT-Targeted Antibody Deal with BeiGene, Retains Rights to Ociperlimab
Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has decided to terminate an option and license...
CSPC Pharmaceutical’s Biosimilar Omalizumab Accepted for Review by China’s NMPA
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that the National Medical Products Administration...
Novartis’s Iptacopan on Track for Priority Review Status in China for PNH Treatment
China’s Center for Drug Evaluation (CDE) website has indicated that Swiss pharmaceutical giant Novartis’ (NYSE:...
Legend Biotech and Janssen Partner with Novartis on Carvykti Manufacturing and Clinical Supply
Legend Biotech Corporation (NASDAQ: LEGN), a China-based biotech firm, and its US partner Janssen Pharmaceutical...
Novartis’ Jakavi Secures NMPA Approval for Acute GVHD Treatment in China
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that it has received a new indication...
Novartis’ Kisqali Demonstrates Improved iDFS in Phase III NATALEE Study for Early Breast Cancer
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that the multi-center, randomized, open-label Phase III...
Novartis’ LNP023 and Janssen’s Tremfya on Track for Breakthrough Designations
The Center for Drug Evaluation (CDE) website indicates that Swiss major Novartis’ (NYSE: NVS) LNP023...
Novartis’ Revolade Approved for Severe Aplastic Anemia in China
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced receiving another indication approval from the National...
Baheal Pharmaceutical Partners with Novartis for Votrient Commercialization
China-based health services and distribution giant Baheal Pharmaceutical Group has struck a partnership with Swiss...
Novartis Q4 Results Show Growth in Innovative Medicines Amid Sandoz Spin-Off Plans
Swiss pharmaceutical giant Novartis (NYSE: NVS) has released its financial results for Q4 and the...
Qilu Pharmaceutical’s Biosimilar Lucentis Accepted for Review by China’s CDE
China-based Qilu Pharmaceutical has announced that its market approval filing for a biosimilar version of...
Novartis’ Kisqali Receives NMPA Approval for Premenopausal Breast Cancer
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced receiving marketing approval from the National Medical...
Suzhou Thery’s Generic Nilotinib Approved by China’s NMPA
China-based Suzhou Thery Pharmaceutical Inc. has announced that the National Medical Products Administration (NMPA) has...
Novartis China Establishes Health Development Fund in Boao Lecheng
Novartis (NYSE: NVS) China has announced the establishment of a health development fund, a significant...
Fudan Team Presents Ribociclib Phase II Bridging Study Results at ESMO Asia
A Fudan University Shanghai Cancer Center team led by Shao Zhimin made an oral presentation...
Novartis Partners with Sinopharm for Commercial Promotion of Gleevec and Exjade in China
Swiss giant Novartis (NYSE: NVS) entered into a promotion agreement with China-based Sinopharm Group Co.,...